Shares of Becton Dickinson (NYSE: BDX) plummeted 5.43% in the intraday trading session, after the medical technology company announced plans to separate its Biosciences and Diagnostic Solutions business, while also lowering its fiscal 2025 revenue guidance.
According to the company, the planned separation aims to enhance strategic focus and enable growth-oriented investments and capital allocation for the two businesses. After the separation, the New BD will be a pure-play medical technology company with expected fiscal 2024 revenue of approximately $17.8 billion, while the Biosciences and Diagnostic Solutions business is expected to have around $3.4 billion in revenue.
Meanwhile, Becton Dickinson lowered its fiscal 2025 revenue guidance from the previous range of $21.9 billion to $22.1 billion to a new range of $21.7 billion to $21.9 billion, which fell short of analysts' consensus estimate of $21.93 billion. However, the company raised its adjusted EPS guidance range to $14.30 to $14.60, up from the previous range of $14.25 to $14.60.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。